Baidu
map

[重复]Crit Care:药物预防应激性溃疡能否让接受肠内营养的ICU患者获益?

2018-02-26 徐晓涵 环球医学网

2018年发表在《Crit Care》上的一项系统评价与meta分析,考察了药物预防应激性溃疡(SUP)对接受肠内营养的重症患者的应激性胃肠道(GI)出血和其他临床结局的获益情况。

2018年发表在《Crit Care》上的一项系统评价与meta分析,考察了药物预防应激性溃疡(SUP)对接受肠内营养的重症患者的应激性胃肠道(GI)出血和其他临床结局的获益情况。

背景:在应激性GI出血风险较高的危重患者中,推荐使用药物SUP。但是,对于接受肠内营养的患者,SUP的预防作用仍不清楚。因此,研究人员对评估药物SUP对接受肠道营养患者的应激性GI出血和其他临床结局作用的随机对照试验(RCTs),进行了一项meta分析。

方法:研究人员对PubMed、Embase和Cochrane数据库进行了检索,从创刊至2017年9月30日。纳入标准是在接受肠道营养的ICU患者中对比药物SUP和安慰剂或无预防的RCTs。结果以风险比(RR)和平均差(MD)及95%置信区间(CI)表示。对异质性、亚组分析、敏感性分析和发表偏倚进行分析。

结果:共7项研究(n=889名患者)。组间GI出血没有显着差异(RR 0.80;95%CI,0.49至1.31,p=0.37)。进一步的亚组分析和敏感分析中也得到同样结果。此外,SUP对总死亡率(RR 1.21;95% CI,0.94至1.56,p?=?0.14)、艰难梭菌感染(RR 0.89;95% CI,0.25至3.19,p?=?0.86)、ICU住院时长(MD 0.04日;95% CI,?0.79至0.87,p?=?0.92)、机械通气的持续时间(MD ?0.38日;95% CI,?1.48至0.72,p?=?0.50)均没有效果,但与医院获得性肺炎风险的增加相关(RR 1.53;;95% CI,1.04 to 2.27;p?=?0.03)。

结论:研究结果证实,在接受肠内营养的ICU患者中,药物SUP没有获益,而且联合干预甚至可能会增加医院获得性肺炎的风险。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1445207, encodeId=a8c3144520ed2, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Wed Feb 28 13:10:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527344, encodeId=5332152e344c6, content=<a href='/topic/show?id=91554929461' target=_blank style='color:#2F92EE;'>#应激性溃疡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49294, encryptionId=91554929461, topicName=应激性溃疡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee2d11842055, createdName=mfx803, createdTime=Wed Feb 28 13:10:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542214, encodeId=04a21542214b5, content=<a href='/topic/show?id=d20a8e9073e' target=_blank style='color:#2F92EE;'>#药物预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87907, encryptionId=d20a8e9073e, topicName=药物预防)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e3b13370459, createdName=ms6829001416292975, createdTime=Wed Feb 28 13:10:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595364, encodeId=575c15953642d, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Wed Feb 28 13:10:00 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1445207, encodeId=a8c3144520ed2, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Wed Feb 28 13:10:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527344, encodeId=5332152e344c6, content=<a href='/topic/show?id=91554929461' target=_blank style='color:#2F92EE;'>#应激性溃疡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49294, encryptionId=91554929461, topicName=应激性溃疡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee2d11842055, createdName=mfx803, createdTime=Wed Feb 28 13:10:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542214, encodeId=04a21542214b5, content=<a href='/topic/show?id=d20a8e9073e' target=_blank style='color:#2F92EE;'>#药物预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87907, encryptionId=d20a8e9073e, topicName=药物预防)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e3b13370459, createdName=ms6829001416292975, createdTime=Wed Feb 28 13:10:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595364, encodeId=575c15953642d, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Wed Feb 28 13:10:00 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1445207, encodeId=a8c3144520ed2, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Wed Feb 28 13:10:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527344, encodeId=5332152e344c6, content=<a href='/topic/show?id=91554929461' target=_blank style='color:#2F92EE;'>#应激性溃疡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49294, encryptionId=91554929461, topicName=应激性溃疡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee2d11842055, createdName=mfx803, createdTime=Wed Feb 28 13:10:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542214, encodeId=04a21542214b5, content=<a href='/topic/show?id=d20a8e9073e' target=_blank style='color:#2F92EE;'>#药物预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87907, encryptionId=d20a8e9073e, topicName=药物预防)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e3b13370459, createdName=ms6829001416292975, createdTime=Wed Feb 28 13:10:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595364, encodeId=575c15953642d, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Wed Feb 28 13:10:00 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1445207, encodeId=a8c3144520ed2, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Wed Feb 28 13:10:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527344, encodeId=5332152e344c6, content=<a href='/topic/show?id=91554929461' target=_blank style='color:#2F92EE;'>#应激性溃疡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49294, encryptionId=91554929461, topicName=应激性溃疡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee2d11842055, createdName=mfx803, createdTime=Wed Feb 28 13:10:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542214, encodeId=04a21542214b5, content=<a href='/topic/show?id=d20a8e9073e' target=_blank style='color:#2F92EE;'>#药物预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87907, encryptionId=d20a8e9073e, topicName=药物预防)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e3b13370459, createdName=ms6829001416292975, createdTime=Wed Feb 28 13:10:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595364, encodeId=575c15953642d, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Wed Feb 28 13:10:00 CST 2018, time=2018-02-28, status=1, ipAttribution=)]

相关资讯

CGH:药物预防ERCP源性胰腺炎(系统综述)

目前关于药物预防内镜逆行胰胆管造影术后诱发胰腺炎(PEP)的临床有效性还存在诸多争议。近日,密歇根大学医学中心和南卡罗莱纳医科大学的研究人员进行了一项评估药物预防内镜逆行胰胆管造影术(ERCP)源性胰腺炎安全性和有效性的系统综述,最新研究成果在线发表于1月8日的Clinical Gastroenterology and Hepatology杂志上。

The Lancet Infectious Diseases:DSM265用于恶性疟疾的药物预防

400mg单剂量的DSM265对于疟疾的预防是安全有效的

Chest:这3种药预防严重脓毒症和脓毒性休克患者器官衰竭效果好

2017年6月,发表在《Chest》的一项由美国科学家进行的回顾性前后研究,考察了氢化可的松、维生素C和硫胺素治疗严重脓毒症和脓毒性休克的有效性。

Baidu
map
Baidu
map
Baidu
map